HEPA - מכפיל EV/EBITDA Hepion Pharmaceuticals, Inc.

This EV/EBITDA price chart for Hepion Pharmaceuticals (HEPA) demonstrates a metric of , while management optimizes clinical trial expenses to attract strategic partners. Hepion Pharmaceuticals (HEPA) is actively developing its portfolio of anti-fibrosis and NASH treatments, confirming the therapeutic value of its developments. The business leverages the massive potential of the anti-inflammatory market, creating solutions for individuals with chronic liver pathologies.

High debt loads for capital-intensive companies create a risk of insolvency during sharp revenue declines. The diversification of Hepion Pharmaceuticals (HEPA) developments across several therapeutic areas mitigates these threats, providing a fundamental margin of safety. By analyzing the Enterprise Value to EBITDA ratio, an investor assesses the total business value relative to operating profit, determining the asset's real attractiveness while accounting for all liabilities.